Licostinel

Licostinel (also known as ABT-894) is a drug that was under development by the pharmaceutical company Abbott Laboratories for the treatment of neuropathic pain and Tourette syndrome. It acts as a nicotinic acetylcholine receptor agonist, specifically at the α4β2 subtype of this receptor, which is believed to be beneficial for these indications.

History

Licostinel was in Phase II clinical trials for neuropathic pain and Tourette syndrome but was discontinued due to lack of efficacy.

Mechanism of action

Licostinel is a nicotinic acetylcholine receptor agonist, specifically at the α4β2 subtype of this receptor. This receptor subtype is thought to be involved in the mediation of pain signals and in the pathophysiology of Tourette syndrome.

Clinical trials

In clinical trials, licostinel was found to be ineffective for the treatment of neuropathic pain and Tourette syndrome. The trials were subsequently discontinued.

See also

• Nicotinic agonist
• Neuropathic pain
• Tourette syndrome

Licostinel Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski